194 related articles for article (PubMed ID: 17634427)
1. c-Jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancer.
Cai C; Hsieh CL; Shemshedini L
Mol Cancer Res; 2007 Jul; 5(7):725-35. PubMed ID: 17634427
[TBL] [Abstract][Full Text] [Related]
2. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation.
Chen SY; Cai C; Fisher CJ; Zheng Z; Omwancha J; Hsieh CL; Shemshedini L
Oncogene; 2006 Nov; 25(54):7212-23. PubMed ID: 16732317
[TBL] [Abstract][Full Text] [Related]
3. ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion.
Cai C; Hsieh CL; Omwancha J; Zheng Z; Chen SY; Baert JL; Shemshedini L
Mol Endocrinol; 2007 Aug; 21(8):1835-46. PubMed ID: 17505060
[TBL] [Abstract][Full Text] [Related]
4. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
[TBL] [Abstract][Full Text] [Related]
5. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
7. Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells.
Yuan H; Gong A; Young CY
Carcinogenesis; 2005 Apr; 26(4):793-801. PubMed ID: 15661808
[TBL] [Abstract][Full Text] [Related]
8. [The roles of c-Jun and CBP in the inhibitory effect of quercetin on prostate cancer cells].
Yuan HQ; Guo HF; He ML; Kong F; Hu XY; Jiang AL; Xu X; Zhang JY; Charles YF
Yao Xue Xue Bao; 2006 Sep; 41(9):819-24. PubMed ID: 17111826
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
10. A cell-specific and selective effect on transactivation by the androgen receptor.
Gordon DA; Chamberlain NL; Flomerfelt FA; Miesfeld RL
Exp Cell Res; 1995 Apr; 217(2):368-77. PubMed ID: 7698238
[TBL] [Abstract][Full Text] [Related]
11. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor overexpression in prostate cancer linked to Pur alpha loss from a novel repressor complex.
Wang LG; Johnson EM; Kinoshita Y; Babb JS; Buckley MT; Liebes LF; Melamed J; Liu XM; Kurek R; Ossowski L; Ferrari AC
Cancer Res; 2008 Apr; 68(8):2678-88. PubMed ID: 18413735
[TBL] [Abstract][Full Text] [Related]
13. Specific block of androgen receptor activity by antisense oligonucleotides.
Hamy F; Brondani V; Spoerri R; Rigo S; Stamm C; Klimkait T
Prostate Cancer Prostatic Dis; 2003; 6(1):27-33. PubMed ID: 12664061
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells.
Briggs J; Chamboredon S; Castellazzi M; Kerry JA; Bos TJ
Oncogene; 2002 Oct; 21(46):7077-91. PubMed ID: 12370830
[TBL] [Abstract][Full Text] [Related]
15. Sterol regulatory element-binding protein-1c represses the transactivation of androgen receptor and androgen-dependent growth of prostatic cells.
Suh JH; Gong EY; Kim JB; Lee IK; Choi HS; Lee K
Mol Cancer Res; 2008 Feb; 6(2):314-24. PubMed ID: 18245227
[TBL] [Abstract][Full Text] [Related]
16. KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells.
Marreiros A; Dudgeon K; Dao V; Grimm MO; Czolij R; Crossley M; Jackson P
Oncogene; 2005 Jan; 24(4):637-49. PubMed ID: 15580298
[TBL] [Abstract][Full Text] [Related]
17. Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer.
Hermans KG; van der Korput HA; van Marion R; van de Wijngaart DJ; Ziel-van der Made A; Dits NF; Boormans JL; van der Kwast TH; van Dekken H; Bangma CH; Korsten H; Kraaij R; Jenster G; Trapman J
Cancer Res; 2008 Sep; 68(18):7541-9. PubMed ID: 18794142
[TBL] [Abstract][Full Text] [Related]
18. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of prostate cancer cell survival after inhibition of AR expression.
Cohen MB; Rokhlin OW
J Cell Biochem; 2009 Feb; 106(3):363-71. PubMed ID: 19115258
[TBL] [Abstract][Full Text] [Related]
20. Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate.
Kinoshita M; Nakagawa T; Shimizu A; Katsuoka Y
Int J Urol; 2005 Apr; 12(4):390-7. PubMed ID: 15948728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
